Sandoz Group AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1986-01-01

Employees: 20K

Market Cap: $19B

Website: http://www.sandoz.com

Clinical Trials

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

Phase 1

Completed

Conditions: Ovarian Cancer
Breast Cancer

Interventions: Drug: Olaparib tablets, 150 mg
Drug: Lynparza® (olaparib) tablets 150 mg

First Posted Date: 2022-02-28

Last Posted Date: 2024-10-03

Lead Sponsor: Sandoz

Target Recruit Count: 70

Registration Number: NCT05258747

Locations: 🇮🇳
Sandoz Investigative Site, Vijayawada, Andhra Pradesh, India

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

Phase 3

Completed

Conditions: Neovascular Age-related Macular Degeneration (nAMD)

Interventions: Drug: SOK583A1 (40 mg/mL)
Device: Prefilled Syringe (PFS)

First Posted Date: 2021-12-17

Last Posted Date: 2022-11-18

Lead Sponsor: Sandoz

Target Recruit Count: 30

Registration Number: NCT05161806

Locations: 🇺🇸
Sandoz Investigational Site, Liverpool, New York, United States

Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold

Phase 3

Not yet recruiting

Conditions: Common Cold

Interventions: Drug: Acetylcysteine
Drug: Paracetamol
Drug: Phenylephrine

First Posted Date: 2021-10-07

Last Posted Date: 2024-08-07

Lead Sponsor: Sandoz

Target Recruit Count: 1002

Registration Number: NCT05070650

Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration

Phase 3

Completed

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Biological: Eylea EU (40 mg/mL)
Biological: SOK583A1 (40 mg/mL)

First Posted Date: 2021-04-29

Last Posted Date: 2024-03-26

Lead Sponsor: Sandoz

Target Recruit Count: 485

Registration Number: NCT04864834

Locations: 🇪🇸
Sandoz Investigational Site, Zaragoza, Spain

Study of LRG-002 Hard Capsules (Lek d.d., Slovenia) Used in the Prophylaxis of Antibiotic-associated Diarrhea in Adults.

Phase 3

Completed

Conditions: Antibiotic-associated Diarrhea

Interventions: Drug: LRG-002
Drug: Placebo

First Posted Date: 2020-03-25

Last Posted Date: 2022-03-14

Lead Sponsor: Sandoz

Target Recruit Count: 520

Registration Number: NCT04321460

Locations: 🇷🇺
Sandoz Investigative Site, Saint Petersburg, Russian Federation

An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.

Phase 1

Terminated

Conditions: Parkinson Disease

Interventions: Drug: Rotigotine TTS (Test)
Drug: Neupro (Reference)

First Posted Date: 2019-12-03

Last Posted Date: 2020-11-09

Lead Sponsor: Sandoz

Target Recruit Count: 31

Registration Number: NCT04183634

Locations: 🇩🇪
Sandoz Investigative Site, Hamburg, Germany

Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis

Phase 3

Completed

Conditions: Rhinosinusitis

Interventions: Drug: acetylcysteine
Drug: Placebo

First Posted Date: 2019-10-10

Last Posted Date: 2021-11-19

Lead Sponsor: Sandoz

Target Recruit Count: 944

Registration Number: NCT04123405

Locations: 🇷🇺
Sandoz Investigative Site, Yaroslavl, Russian Federation

This Was a Clinical Study Investigating the Moisturization and Desquamation Effect of AmLactin® Rapid Relief Restoring Lotion + Ceramides on Dry Skin in Healthy Female Volunteers. AmLactin® Rapid Relief is an Over-the-counter Cosmetic

Not Applicable

Completed

Conditions: Dry Skin

Interventions: Other: AmLactin® Rapid Relief

First Posted Date: 2019-09-11

Last Posted Date: 2023-05-10

Lead Sponsor: Sandoz

Target Recruit Count: 56

Registration Number: NCT04085809

Locations: 🇺🇸
Sandoz Investigational Site, High Point, North Carolina, United States

Study to Test the Hypothesis of Non-inferior Efficacy and Safety of Ferrum Lek® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Lek d.d., Slovenia), as Compared With MALTOFER® (Vifor S.A., Switzerland), in Subjects With Mild and Moderate Iron Deficiency Anemia.

Phase 3

Completed

Conditions: Mild and Moderate Iron-deficiency Anaemia

Interventions: Drug: Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia)
Drug: MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland)

First Posted Date: 2019-06-20

Last Posted Date: 2021-07-12

Lead Sponsor: Sandoz

Target Recruit Count: 267

Registration Number: NCT03993288

Locations: 🇷🇺
Sandoz Investigative Site, Yaroslavl, Russian Federation

Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients.

Phase 1

Withdrawn

Conditions: Kidney Transplant

Interventions: Drug: Advagraf®
Drug: Generic tacrolimus

First Posted Date: 2019-06-07

Last Posted Date: 2019-09-17

Lead Sponsor: Sandoz

Registration Number: NCT03978494

Locations: 🇩🇪
Sandoz Investigative Site, Kiel, Germany

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy